Literature DB >> 16928218

Hepatic arterial flow becomes the primary supply of sinusoids following partial portal vein ligation in rats.

Yukihiro Yokoyama1, Andrew Wawrzyniak, Amir M Sarmadi, Rajiv Baveja, Helen E Gruber, Mark G Clemens, Jian X Zhang.   

Abstract

BACKGROUND AND AIM: Partial portal vein ligation (PPVL) is a commonly used procedure to induce prehepatic portal hypertension in animal models. The aim of this study was to test the hypothesis that the hepatic arterial flow becomes the primary source feeding the sinusoids in the liver after PPVL.
METHODS: Sprague-Dawley rats underwent either sham operation or partial portal vein ligation (PPVL). The number of vessels in the liver at 2 weeks postoperatively was determined by factor VIII immunolocalization and the gene expression of angiogenic factors was assessed by RT-PCR. The total hepatic arterial supply to the liver was measured using the fluorescent microsphere injection technique. To further test the hypothesis, two additional groups of rats underwent hepatic artery ligation (HAL) or PPVL plus HAL (PPHAL). The integrity of hepatic microcirculation was then evaluated in all four groups by intravital microscopy.
RESULTS: At 2 weeks after operation, the number of vessels detected by factor VIII staining was significantly higher in PPVL compared to sham. Densitometric analysis of RT-PCR bands revealed a significant increase of vascular endothelial growth factor gene expression in PPVL compared to sham. Arterial flow to the liver measured by fluorescent microspheres was increased by 190% in PPVL compared to sham. When all four groups were compared, no prominent histological abnormality was observed in sham, HAL, and PPVL groups; however, PPHAL livers showed focal necrosis and inflammatory cell infiltration around the portal triads. Additionally, only the PPHAL livers showed a decreased sinusoidal diameter and significantly lower perfusion index (PPHAL 42.9+/-6.1; sham 85.7+/-7.0, PPVL 80.2+/-6.5, HAL 70.9+/-4.5).
CONCLUSIONS: These results suggest that the hepatic artery flow becomes the primary source for the blood supply of sinusoids and the compensatory change in the hepatic arterial system plays a critical role in maintaining microcirculatory perfusion following the restriction of the portal vein flow by PPVL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928218     DOI: 10.1111/j.1440-1746.2006.04460.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  Next generation sequencing of progressive colorectal liver metastases after portal vein embolization.

Authors:  Eve Simoneau; Jarred Chicoine; Sarita Negi; Ayat Salman; Anthoula Lazaris; Mazen Hassanain; Nicole Beauchemin; Stephanie Petrillo; David Valenti; Ramila Amre; Peter Metrakos
Journal:  Clin Exp Metastasis       Date:  2017-07-31       Impact factor: 5.150

Review 2.  The portal hypertension syndrome: etiology, classification, relevance, and animal models.

Authors:  Jaime Bosch; Yasuko Iwakiri
Journal:  Hepatol Int       Date:  2017-10-24       Impact factor: 6.047

Review 3.  Tumour progression and liver regeneration--insights from animal models.

Authors:  Chetana Lim; Francois Cauchy; Daniel Azoulay; Olivier Farges; Maxime Ronot; Marc Pocard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-04-09       Impact factor: 46.802

4.  In situ splitting after selective partial portal vein ligation or simultaneous hepatic artery ligation promotes liver regeneration.

Authors:  Li-Bin Yao; Chong-Hui Li; Xiao-Juan Wu; Xue-Dong Wang; Xin-Lan Ge; Ai-Qun Zhang; Xiao-Cheng Zhu; Yong Shao; Jia-Hong Dong
Journal:  Sci Rep       Date:  2018-06-07       Impact factor: 4.379

5.  Visualization of acute liver damage induced by cycloheximide in rats using PET with [(18)F]FEDAC, a radiotracer for translocator protein (18 kDa).

Authors:  Akiko Hatori; Joji Yui; Lin Xie; Tomoteru Yamasaki; Katsushi Kumata; Masayuki Fujinaga; Hidekatsu Wakizaka; Masanao Ogawa; Nobuki Nengaki; Kazunori Kawamura; Ming-Rong Zhang
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.